## IN THE SPECIFICATION

## AMENDMENTS TO THE SPECIFICATION

Applicants request entry of the substitute specification that accompanies these papers, pursuant to 37 C.F.R. §1.125(b). A marked-up copy of the substitute specification showing the matter being added to and the matter being deleted from the specification of record is included herewith.

Amendments are indicated by the presence of vertical lines present at the left and right sides of amended text. Within those vertical lines, deletions are indicated by strikethough, additions by underlining. Applicants through their attorneys state that no new matter is presented therein.

Specifically, the substitute specification seeks to add SEQ ID numbers conforming with US national requirements.

The Title of the application has been amended from "Somatostatin Vectors" to "Peptide Vectors" to more accurately reflect that additional vectors are present and claimed in addition to somatostatin vectors, e.g., LHRH and bombesin. Support is apparent throughout the specification, see, e.g., page 5, paragraph 13 of the original specification.

On page 6, paragraph 16, the somatostatin analog has been amended to Caeg-cyclo(DCys-<u>3</u>Pal-DTrp-Lys-DCys)-Thr(Bzl)-Tyr-NH<sub>2</sub>. Support for correction of this typographical error can be found on page 55, Example 47 of the specification.

Applicants amended page 66, Example 74, to include the full names of the following chemicals:

Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate, or "BOP";

Tetrakis(triphenylphosphine) palladium (0), or Pd(PPh<sub>3</sub>)<sub>4;</sub> and

Tributyltin hydride, or Bu<sub>3</sub>SnH.

These are common reagents used in peptide synthesis and would be readily apparent to those skilled in the art.

Additional typographical errors are corrected. No new matter is presented.